To study whether volume-based indices of fluorine 18 fluorodeoxyglucose positron emission tomographic (PET)/ computed tomographic (CT) imaging is an accurate tool to predict the amount of residual viable tumor after induction chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC).
Purpose:
To study whether volume-based indices of fluorine 18 fluorodeoxyglucose positron emission tomographic (PET)/ computed tomographic (CT) imaging is an accurate tool to predict the amount of residual viable tumor after induction chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC).
Materials and Methods:
This study was approved by institutional review board with waivers of informed consent. Twenty-two patients with locally advanced NSCLC underwent surgery after induction chemotherapy. All had pre-and posttreatment FDG PET/CT scans. CT largest diameter, CT volume, maximum standardized uptake value (SUV max ), mean SUV (SUV mean ), metabolic tumor volume (TV), and total lesion glycolysis of primary tumor were calculated. Changes in tumor measurements were determined by dividing follow-up by baseline measurement (ratio index). Amounts of residual viable tumor, necrosis, fibrous tissue, inflammatory infiltrate, and Ki-67 proliferative index were estimated on resected tumor. Correlations between imaging indices and histologic parameters were estimated by using Spearman correlation coefficients or Mann-Whitney tests. 
Results:

Conclusion:
TV and total lesion glycolysis ratios were the only indices correlated with residual viable tumor after induction chemotherapy in locally advanced NSCLC.
Materials and Methods
Patients and Induction Chemotherapy
This study was approved by our institutional review board with waivers of informed consent. Between January 2009 and June 2011, 34 consecutive patients with potentially resectable biopsy-proved stage III NSCLC were treated with induction chemotherapy and underwent FDG PET/computed tomographic (CT) imaging before and after the induction treatment. In addition to FDG PET/CT, initial routine staging procedures consisted of a clinical examination, including lung function tests, bronchoscopy and/or mediastinoscopy, thoracic enhanced CT, and brain imaging, by using enhanced CT or magnetic resonance imaging. Disease had been staged according to the seventh edition of the International Union Against Cancer TNM classification (18). Operability was assessed by the performance status, lung function status, and cardiac status of the patient. Induction treatment was composed of three cycles of objective criterion of chemotherapy response than imaging criteria. The most recent study showed that the percentage of residual viable tumor cells helps predict overall and diseasefree survival in patients with resected NSCLC after induction chemotherapy even when controlled for pathologic stage (7) . Metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is increasingly used for prediction of histologic response after chemotherapy. Despite existing guidelines (8,9), there is an ongoing debate about the parameters that should be measured to assess therapeutic response. Positive correlations between standardized uptake value (SUV) changes during treatment and histopathologic regression have been observed in NSCLC (10-13). However, studies about accuracy of PET for prediction of histologic response after induction treatment in NSCLC have yielded contradictory results (14,15). Scanning protocols, SUV measurement, and best cutoff values were not standardized, and a sound meta-analysis is difficult (10-13). Maximum SUV (SUV max ), which is used in most studies, depends on several acquisition and processing parameters and does not reflect the spatial distribution of the tracer within the lesion. Our assumption was that measurement methods that accounted for the metabolically active tumor volume might add relevant information regarding residual tumor cells (16,17). Our purpose was to study whether volume-based parameters could bring additional information compared with SUV measurements to predict the residual viable tumor seen at histologic L ung cancer is one of the most frequent malignant tumors and represents the leading cause of death by cancer in Europe and in the United States (1, 2) . Surgery is the treatment of choice in early-stage non-small cell lung cancer (NSCLC). The treatment of locally advanced NSCLC has evolved during the past 2 decades, and the current standard of care is combinedmodality therapy, including chemotherapy, radiation therapy, and surgery (3). Induction chemotherapy followed by surgery has been used in stage III cancer to address the high rate of local and systemic failure (4) . Induction treatment before surgery can produce a tumor downstaging that increases the likelihood of complete resection, organ preservation, and long-term survival. Therefore, an accurate prediction of tumoral response after induction chemotherapy in stage III NSCLC is crucial to determine which patients will benefit from surgery.
Several studies (5,6) have suggested that the degree of residual viable tumor after induction therapy, determined by histopathologic findings in the resected tumor, may be a more
Implication for Patient Care
n Volume-based indices (TV and total lesion glycolysis ratios) on FDG PET/CT scans help predict residual viable tumor after preoperative chemotherapy in locally advanced NSCLC and might help identify patients who will benefit from the surgery. n Maximum standardized uptake value (SUV) and mean SUV ratios between the two scans were correlated with Ki-67 proliferative index after induction chemotherapy (r = 0.62; P = .003; and r = 0.60; P = .004, respectively). 
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[AQ5] The number of slides examined per case ranged from three to 11 (median, five slides). All slides were scanned at magnification of 3400 through a highresolution digital slide scanner (NanoZoomer 2.0 HT; Hamamatsu Photonics KK, Hamamatsu City, Japan), and two pathologists (J.C., C.P.) who were blinded to clinical and radiologic findings independently reviewed the results using viewer software (NDP; Hamamatsu Photonics KK). For each slide, the zone that contained the tumor and/or evidence of tumor regression was the zone of interest, and its area was measured. In this zone, the percentage of each of the following items was assessed: (a) remaining viable tumor cells, (b) necrosis, and (c) fibrous tissue (including fibrous stroma, scar fibrosis, and elastosic replacement) (Fig 1) . A weighted average of each of these values was calculated for all slides, where the weight for each slide was equal to the tumor area in the slide so that a percentage of viable tumor, necrosis, and fibrous tissue cells was determined for each tumor. The inflammatory infiltrate (composed of lymphocytes and/or neutrophils) and the presence of foamy macrophages were both assessed by using a binary semiquantitative scale (sparse or moderate and abundant) (Fig 1) . In case of discrepancy (10% or one point of intensity), slides were reviewed simultaneously by both pathologists, and consensus was obtained.
Ki-67 proliferative index immunostaining for each tumor was obtained on the part with highest tumor cellularity by using a mouse monoclonal antibody (MIB-1; DAKO, Carpinteria, Calif; dilution 1:50) and a staining platform (Ventana BenchMark XT; Ventana Medical Systems, Tucson, Ariz). Any intensity of brown nuclear staining was considered to indicate positivity. Proliferative index percentage was assessed for 1000 cells of the most proliferative area at magnification of 3400 (19). a platinum-based chemotherapy given every 3 weeks. Staging was repeated after completion of induction chemotherapy, including thoracic enhanced CT and FDG PET/CT. Patients with tumoral and/or mediastinal node downstaging according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria underwent surgery (22 of 34 patients). These 22 patients were the population study. Patients without mediastinal node downstaging or with a progressive disease underwent a thoracic radiation therapy with or without chemotherapy.
Patient age and sex, histologic subtypes, type of chemotherapy, and type of surgery are presented in Table 1 . The study population consisted mostly of men (15 of 22 patients), and 14 of the patients had stage IIIA N2 disease. Six patients had stage IIIB (TNM stage T4N2M0) and two patients had stage IIIA non-N2 disease. The histopathologic subtypes were squamous cell carcinoma (11 patients), adenocarcinoma (eight patients), and large cell carcinoma (three patients). After the course of the platinum-based induction chemotherapy, all patients underwent surgical treatment: 16 patients underwent lobectomy, four underwent pneumonectomy, and two underwent bilobectomy. All patients had a complete resection of the primary tumor with negative margins and complete thoracic lymphadenectomy. Five of the 22 patients had N2 disease according to postsurgical histologic analysis, and they underwent subsequent mediastinal radiation therapy.
Histologic Assessment
All slides (107 slides) stained with hematoxylin-eosin safran were available for the 22 patients, and initial pathologic reports were retrieved from the archives. At least one section per 1 cm of tumor had been obtained during sampling. In cases with no residual carcinoma, the entire tumoral mass was submitted. Gross pathologic reports were reviewed to ensure that no necrotic or fibrotic core had been left unsampled. The following general characteristics of the tumor were CT volume of each primary tumor was computed by using a commercially available lung analysis software package (CT Oncology Engine; Siemens, Forchheim, Germany) (17,24). On PET images, each primary lung tumor was automatically outlined by using the fit method described by Tylski et al (25) . SUV max and mean SUV (SUV mean ) were then calculated, which resulted in the tumor volume (TV). SUV mean was intrinsically corrected for partial volume effect because the sampling and resolution effects were modeled in the tumor volume estimation method (25) . Total lesion glycolysis was also calculated by using the following equation: total lesion glycolysis = SUV mean 3 TV. Changes in the primary tumor features were calculated by using index ratios that were obtained by dividing the follow-up by the baseline measurement. Index ratios that corresponded to changes in ordered subset-time of flight list-mode iterative algorithm with two iterations and 33 subsets, including attenuation and scatter corrections. A single-scatter simulation model was used for scatter correction (22) . No postreconstruction smoothing filter was used. The image voxel size was 4 3 4 3 4 mm for PET and 1.17 3 1.17 3 1.5 mm for CT. SUVs were calculated from the reconstructed activity concentration values and were normalized to body weight.
Image Analysis PET/CT and enhanced CT scans were used to characterize lung primary tumor and mediastinal nodes before and after induction chemotherapy (M.S., 10 years of experience). The largest diameter of the primary tumor (ie, the CT diameter) was measured from a single enhanced CT transverse image described in the RECIST 1.1 guidelines (23). The
FDG PET/CT Protocol
Baseline FDG PET/CT imaging was performed within 1 month of the start of chemotherapy. Follow-up FDG PET/CT imaging was performed in all patients approximately 2 weeks after administration of the last dose of the chemotherapy. PET/CT imaging was performed 60 minutes after intravenous injection of 3 MBq/kg of FDG. Serum glucose level was less than 1.4 g/L at the time of injection for all patients. All FDG PET/CT images were obtained by using a PET/CT scanner (Gemini TF; Philips Medical Systems, Best, the Netherlands) (20, 21) . Time per bed position was 105 seconds. CT images were obtained without injection of contrast media by using the following settings: 120 kV; 100 mA; collimation, 16 3 1.5 mm; pitch, 0.69; section thickness, 3 mm; increment, 1.5 mm. PET images were reconstructed by using a blob Tables 3 and 4 .
THORACIC IMAGING:
CT and PET indices before induction chemotherapy.-None of the baseline indices was correlated with the percentage of residual tumor cells. Large tumors characterized with a large diameter or volume at CT imaging before treatment exhibited more necrosis according to histologic analysis (Table  3) . Large tumors characterized with a large CT diameter, CT volume, TV, and total lesion glycolysis were associated with a significant infiltrate of foamy macrophages (P , .05) ( Table 4) .
CT and PET indices after induction chemotherapy.-After induction chemotherapy, large tumors that were characterized by large CT diameter, CT volume, and TV exhibited more necrosis at histologic analysis (Table  3) . SUV indices after treatment were positively correlated with a high proliferative index (r = 0.49; P , .05) and the presence of necrosis (r = 0.63; P , .005), but also negatively correlated with the amount of fibrous tissue (r = 20.46; P , .05). Large tumors characterized with a high CT diameter were associated with a significant infiltrate of foamy macrophages.
PET index ratios.-TV ratio was the only index that correlated with the percentage of residual viable tumor (r = 0.61 [95% confidence interval: 0.24, 0.81]; P = .003) ( Table 3, Fig 2) . SUV max and SUV mean ratios were moderately correlated with the percentage of residual viable tumor, but these correlations were not significant (r = 0.38 [95% confidence interval: 20.06, 0.68]; that the median ratios of CT volume, TV, and total lesion glycolysis were all below 0.5, whereas the median ratios of CT diameter and SUV indices were above 0.57.
Histologic Results of the Primary Tumor
Histologic characterizations of the primary tumors are shown in Table 1 . Two complete responses were observed, both in squamous cell carcinoma. The proportion of residual tumor cells in other cases ranged from 13% to 79% (median, 45%). Median proportions of necrosis and fibrosis were 8% (range, 0%-47%) and 40% (range, 10%-100%), respectively. Moderate to abundant inflammatory infiltrate was found in 11 cases (50%). Moderate to abundant foamy macrophages were seen in five cases (23%).
In 15 of 22 patients, the following features specifically associated with therapy-induced regression were observed: foam-cell rim surrounding necrosis, vascular granulation tissue adjoining scarred fibrosis, cholesterol clefts, and/or multinucleated giant cells (5, 6) .
Residual viable tumor and proliferation index were moderately correlated (r = 0.49; P = .02). Residual viable tumor and proliferative index Ki-67 were negatively correlated with the amount of fibrous tissue (r = 20.9; P , .001; and r = 20.51; P = .02, respectively).
Correlation between Imaging Indices and Histologic Analysis
The results of the correlation between CT and PET indices and histologic CT size, SUV max , SUV mean , TV, and total lesion glycolysis were obtained for each lesion. Measurements were performed by using software (Planet Onco; Dosisoft, Cachan, France).
Statistical Analysis
Spearman rank correlation coefficients or Mann-Whitney tests were calculated to characterize the association between imaging parameters and histologic parameters.
Associated P values and 95% confidence intervals were calculated. Considering the sample size (n = 22) as well as an expected correlation coefficient set to 0.5, 95% confidence intervals around the correlation coefficient could be estimated with a precision around 0.3. The power of these analyses is greater than 0.8 when the correlation coefficient is greater than 0.5.
Despite the low number of patients, multivariate linear regressions were performed to provide head-to-head comparison between TV ratio and SUV max ratio. Because total lesion glycolysis is calculated from SUV mean , head-to-head comparison between total lesion glycolysis with SUV max was not possible. The objective was to study whether the TV ratio was an independent predictor after adjustment for the effect of SUV max . The normality hypothesis of TV and SUV max needed for the linear regression analysis was successfully tested with Kolmogorov tests.
Because statistical analysis involved 108 correlations and associated tests (18 regressor criteria and six dependent variables), analyses were conducted in a stepwise manner to control a family-wise error rate of 5%.
Analyses were performed by using statistical software (R statistical software version 2.15.2, R Foundation for Statistical Computing, Vienna, Austria; and SAS version 9.1, SAS Institute, Cary, NC).
Results
Imaging Results
Imaging results of CT and PET before and after induction chemotherapy are described in Table 2 . Results showed (26) . Moreover, all slides were digitized and reviewed by two pathologists to minimize the intra and inter observer variability. In this study, tumor reduction assessed by metabolic volume changes was more accurate than that obtained by using changes in conventional indices, such as SUVs, CT diameter, or CT volume. Our results are in line with a recent report on breast tumor under induction treatment, where authors suggested that total lesion glycolysis changes predicted histopathologic tumor response with higher accuracy than did measurements of changes in SUV (27) . Similarly, volumetric changes under treatment measured in FDG PET images could be more reliable than SUV changes in terms of survival in stage III-IV NSCLC factors (17,28).
TV and total lesion glycolysis, as defined in our study, can be computed easily and rapidly by using a semiautomatic adaptive threshold method with minimal interobserver variability. The segmentation method used here yields accurate tumor volume and SUV estimates (25) . This method assumed that (r = 0.57 [95% confidence interval: 0.18, 0.80]; P = .006). An illustration of a mismatch between TV and SUV max ratios is shown in Figure 3 .
CT volume ratios were neither correlated with the amount of residual viable tumor nor with the proliferative index Ki-67 (Table 3) . None of the ratios was correlated with the presence of inflammatory infiltrate or foamy macrophages (Table 4) .
Discussion
In this study, we evaluated the value of metabolic volumetric indices for prediction of the amount of residual viable tumor after induction chemotherapy in NSCLC. The residual viable tumor is the most validated histologic criteria for prognosis in patients with resected NSCLC after induction chemotherapy (5-7). Posttherapeutic SUV P = .08; and r = 0.37 [95% confidence interval: 20.07, 0.68]; P = .09, respectively). A multivariate regression model of the percentage of residual viable tumor, including TV ratio and SUV max ratio, demonstrated that TV ratio was an independent predictive parameter after adjusting for the effect of SUV max , but the reverse was not true. In this model, TV ratio significantly correlated with the percentage of residual viable tumor (P = .05), unlike SUV max (P = .61).
SUV max and SUV mean ratios were correlated with Ki-67 proliferative index (r = 0.62 [95% confidence interval: 0.24, 0.82]; P = .003; and r = 0.60 [95% confidence interval: 0.21, 0.81]; P = .004, respectively) ( Table 3, Fig 2) . Total lesion glycolysis ratio was moderately correlated with the percentage of residual viable tumor (r = 0.53 [95% confidence interval: 0.13, 0.78]; P = .01) and with Ki-67 proliferative index Note.-Data in parentheses are P values. TLG = total lesion glycolysis.
* Statistically significant according to the stepwise analysis. † P , .05 as exploratory analysis.
THORACIC IMAGING: Indices Q5in Fluorine 18 Fluorodeoxyglucose PET/CT in Non-Small Cell Lung Cancer Soussan et al posttherapeutic SUV mean or SUV mean ratios and the Ki-67 proliferative index. Previous studies regarding FDG uptake changes after induction treatment in NSCLC showed contradictory results. On the one hand, a reduction in SUV max tends to be greater in complete that these volumes were differently affected by partial volume effect. Intrinsic partial volume effect correction used in this study could have helped to reduce the effect of the partial volume effect confounding factor, which would highlight the correlation between the tumor image could be modeled as the convolution of the actual tumor volume of uniform activity with a threedimensional Gaussian function that described the local spatial resolution in the reconstructed image. Despite the high degree of necrosis observed in some tumors after treatment (median, 8%; range, 0%-47%), we did not observe substantial hypometabolic tumoral area with visual analysis, and that could bias the results of the segmentation method. Furthermore, the fit method used in this study led to SUVs that were intrinsically corrected for partial volume effect (25) . Partial volume effect can severely bias SUV estimates, especially in lesions that are small in size (ie, lesions that are less than three times the full width at half maximum of the reconstructed image resolution) (29) . In our study, we observed strong changes in metabolic volumes before and after treatment, which suggested THORACIC IMAGING: Indices Q5in Fluorine 18 Fluorodeoxyglucose PET/CT in Non-Small Cell Lung Cancer Soussan et al presented a higher amount of necrosis and a higher uptake than smaller tumors can also explain the link between SUV and necrosis. Finally, the time delay between PET imaging and surgery cannot exclude the presence of residual hypoxic, glucose-consuming cells at the time of PET acquisition that became areas of necrosis at the time of surgery. Several limitations should be mentioned. First, this study included a small number of patients. Nevertheless, our population was homogeneous and included only patients with stage III disease who all received platinumbased induction chemotherapy. The macrophages. This discrepancy can be explained by the use of chemotherapy alone as an induction treatment in our study, whereas radiation therapy combined with chemotherapy could have contributed to a more intense inflammatory response (15). Furthermore, other factors, such as hypoxia marker (ie, HIF-1 alpha) can contribute to the tumor uptake (31) . Postinduction SUVs were also positively correlated with the presence of necrosis in this study. One explanation is that hypoxia can cause necrosis, but this is also a factor that contributes to the tumor uptake. Furthermore, the fact that larger tumors histologic responders than in incomplete responders (11, 13, 30) . On the other hand, several studies indicated that FDG uptake does not reliably predict pathologic response after induction treatment (14). Our results showed that postinduction SUVs were positively correlated with Ki-67, but not with the residual viable tumor. In addition, postinduction SUV should be interpreted with caution because they can be caused by macrophage infiltration and not viable tumor tissue (15). We did not find any correlation between posttreatment SUVs and inflammatory infiltrate or the presence of foamy . This case illustrates a mismatch between high decrease in TV and total lesion glycolysis and an increase in SUV max . FDG PET was performed (a) before and (b) after three cycles of induction chemotherapy. SUV max , TV, and total lesion glycolysis ratios were respectively 1.25, 0.2, and 0.2. (c) Histologic analysis of the entire resected specimen showed 30% of residual tumor cells (hematoxylin-eosin stain; scale bar: 100 µm; residual tumor cells [1] , necrosis [2] , and inflammatory cells [3] ), (d) whereas proliferative index Ki-67 was estimated at 80% (immunohistochemical stain). In addition, the small number of patients decreased the statistical power of the analyses when the correlation coefficients were less than 0.5, especially regarding the correlations between SUV max or CT diameter ratios with the amount of residual tumor cells. However, the results of the stepwise analysis suggest that our conclusions were robust, despite the low number of patients. Second, the time to surgery varied from patient to patient, from 3.4 weeks to 11.8 weeks, based on the assumption of ongoing histopathologic changes between the end of chemotherapy and tumor removal. However, the variable time to surgery did not correlate with any of the imaging parameters and did not have a statistically significant effect on the results of the multivariate models. Finally, metabolic volume of pathologic lymph nodes was not taken into account because the delineation was hampered by the mediastinal background activity.
Although it requires further validation, prospective histopathologic estimation of the quantity of residual tumor cells appears to be an accurate prognostic factor in NSCLC treated with induction chemotherapy. Conversely, necrosis alone is not a good marker of response to treatment because it can be replaced by elastosic or scar tissue. The use of fibrous tissue to evaluate response is also problematic because it is difficult to distinguish between treatment-related fibrosis and fibrosis that is not related to treatment. To enhance prognostic accuracy of residual tumor cells, it could be interesting to refine the evaluation of cell viability and the importance of cytologic changes observed in some tumors after induction (5).
In conclusion, TV and total lesion glycolysis ratios helped predict residual viable tumor to preoperative chemotherapy in locally advanced NSCLC. SUV ratios were correlated with proliferative activity of the tumor. Therefore, a combination of metabolic and
